BIOAF Stock UPDATES Bioasis Technologies (BIOAF) 1.0700 09/10/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bioasis Technologies (BIOAF) 1.0700 $BIOAF

biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
Marketwire - Tue Sep 09, 8:36AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC" , will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcend(pep), to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme beta-hexosaminidase subunit beta ("HEXB" , which is functionally deficient in sufferers of Sandhoff Disease.

biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis
Marketwire - Thu Sep 04, 8:04AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), announces that the Natural Sciences and Engineering Research Council of Canada ("NSERC" has awarded a grant to the University of British Columbia ("UBC" in support of the university's collaborative research and development programs with biOasis Technologies Inc. The University and biOasis continue to develop biOasis' extensive intellectual property relating to Transcend and Transcendpep, protein vectors designed to shuttle existing therapeutic drugs across the Blood-Brain Barrier ("BBB" for the potential treatment of previously untreatable Central Nervous System ("CNS" diseases and conditions.

biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds
Marketwire - Fri Aug 29, 5:14PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) (the "Company" is please to announce it has closed its non-brokered private placement announced on August 8th, 2014. The Company has issued 1,694,447 units (each a "Unit" , including an over allotment of 94,477 Units, at a price of CDN$0.95 per unit, for gross proceeds of CDN$1,609,753.15. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$1.20 per share for a period of twelve months up to and including August 29th, 2015, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder's fees of CDN$101,460 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until December 30th, 2014. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business.

WSA Talks to Two Dual-Listed Companies Making Waves
Marketwire - Thu Aug 21, 1:00PM CDT
Wall Street Analyzer's CEO Interview Series

biOasis issues up to 1.6m units in non-brokered private placement
M2 - Mon Aug 11, 3:29AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) reported on Friday the launch of a non-brokered private placement of up to 1,600,000 units.

biOasis Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 8:10PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company" announces a non-brokered private placement of up to 1,600,000 units (each a "Unit" at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant" . Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $1.20 per share for a period of twelve months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 Protection of Minority Security Holders in Special Transactions ("MI 61-101" . The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization.

biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
Marketwire - Fri Jul 25, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose.

biOasis Appoints New Chief Financial Officer and Corporate Secretary
Marketwire - Fri Jun 20, 6:30PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of British Columbia Faculty of Law who also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.

biOasis Enters Investor Relations Agreement with Gale Capital Corporation
Marketwire - Mon Jun 16, 8:02AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company" is pleased to announce that is has retained Gale Capital Corporation ("Gale Capital" effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program.

biOasis awarded patent allowances for Lysosomal Storage Disease therapeutic in Europe and Canada
M2 - Fri Mar 28, 3:37AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) disclosed on Thursday the receipt of notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".

biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Marketwire - Thu Mar 27, 8:03AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".

biOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's Transcend
Marketwire - Mon Mar 17, 8:05AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 36

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 156

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 68

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 50

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 10

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 165

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

Weave Partners with Affordable Care to Transform Patient Services

Updated Category News Views 213

Weave and Affordable Care: A Game-Changer for Dental Practices In today's competitive healthcare landscape, enhancing patient experience and operational efficiency is paramount. Recently, Affordable Care made a significant decision in choosing Weave as the go-to platform for patient communications, engagement, and payments. This strategic partnership aims to revolutionize...

Continue Reading
Exploring the Future Growth of Warehouse Management Systems

Updated Category News Views 207

Market Growth and Dynamics Overview The Warehouse Management System (WMS) market is witnessing remarkable growth, fueled by the surge in e-commerce and technology advancements. According to recent reports, this sector was valued at USD 3.50 billion in 2023, with expectations to reach USD 13.53 billion by 2032. This rapid ascent represents a compound annual growth rate...

Continue Reading
ArcSpan Technologies Partners with Major Publishers for Growth

Updated Category News Views 169

ArcSpan Technologies Partners with Leading Publishers ArcSpan Technologies, a recognized leader in AI-powered audience monetization solutions for global publishers, is thrilled to announce new partnerships with prominent publishers like A360, Sundial Media Group, USNews, and MediaCorp. These influential entities have chosen to implement ArcSpan's Audience Monetization...

Continue Reading
AI Revolutionizes Home Care: Balance of Promise and Peril

Updated Category News Views 20

AI in Home Care: Promise Meets Peril Ever wonder how technology's race to the future impacts the dustier corners of our lives? Well, AI is hitting home care in a big way, or so the National Council on Aging (NCOA) claims in their latest series, A New Era of Care. But before you start imagining a Jetsons-style home nurse, let's break down what's happening and why folks are...

Continue Reading
Whitestone Development and Empower CDC Innovate with Generators

Updated Category News Views 352

In a bold move shaking up the Houston real estate scene, Whitestone Development, Inc. has teamed up with Empower Community Development Corporation to roll out a pioneering residential community called Berry Square. This isn't just another cookie-cutter neighborhood; it's the first of its kind to throw a whole-home generator into every single house—a major nod towards...

Continue Reading